BVI Medical has received FDA approval for its FINEVISION HP (hydrophobic) trifocal intraocular lens (IOL), a third generation premium lens.
First, a look at this company.
The Walham, Massachusetts-based BVI Medical is a medical equipment manufacturer specializing in the surgical ophthalmic space.
- Its product portfolio of ophthalmic equipment, devices, instruments, and surgical fluids is designed for procedures such as: cataract, glaucoma, and vitreoretinal, among others.
And on the lens front?
The company offers a wide range of categories, including: trifocal and trifocal toric IOLs (our focus); premium monofocal and premium monofocal toric IOLs; as well as monofocal and monofocal toric IOLs.
Talk about this FINEVISION brand.
First, you’ll need to know about the original FINEVISION technology (the basis for these IOLs).
- This was originally launched in 2010 as BVI’s original diffractive trifocal IOL optic that combined two profiles to give patients intermediate vision—without impairing near and distance vision acuities (VA).
Fast forward to 2023: The FINEVISION HP IOL family was first introduced in Japan and included hydrophobic, diffractive trifocal IOLs designed to provide continuous vision across distance, intermediate, and near focal points.
- Per BVI: FINEVISION HP is reported to be the “world’s first trifocal IOL,” serving as a benchmark in trifocal innovation and gold standard in cataract surgery.
- See here for a look at all five lenses in this brand.
And now to the newest addition.
FINEVISION HP (along with the HP Toric) IOLs are designed to reduce the need for spectacles via those aforementioned vision capabilities.
A few unique components about this lens:
- Utilizes BVI’s patented GFY hydrophobic raw acrylic material designed to be glistening-free and optimized for long-term optical clarity
- This material is Grade 0 based on the Miyata glistening scale (in vitro)
- Is built on the company’s POD (double C-loop) haptic platform, which enables rotational stability, good centration, and predictable behavior in the capsular bag
- Features an increased contact angle and 4-point contact compared to conventional C-loop designs
- Offers optimized near vision (with the highest energy split allocated) and a high add power of 3.5 diopters (D)
- Enables an optimized range of vision: two complementary add powers of 3.5 D and 1.75 D
Let’s talk proprietary technology.
The trifocal IOL also incorporates BVI’s CoPODize technology.
What this does: Combines two key concepts across the entire ocular surface:
- Convolution for moderating the intensity of photic phenomena, such as glares and halos, by smoothing the transitions
- Apodization refers to the gradual tapering of diffractive step height from the center to the periphery of the lens—all to optimize light distribution under varying pupil sizes and lighting conditions
Click here for a visual of this tech in action.
And in terms of supporting clinical data …?
As BVI noted, real-world clinical findings on the FINEVISION HP IOL have spanned over 10 years—and not to mention there have been “millions of successful implantations and strong surgeon preference” in its favor.
- And as one recent analysis of 18 clinical studies on the lens concluded: “FineVision HP IOL provides good refractive outcomes and excellent visual performance when implanted.”
Where can I get more technical information on this?
Click here for more specifications and check out the official FINEVISION HP website.
Now to the question of availability—when can we expect that?
BVI plans to “methodically” roll out the lens over the next year.
- Reach out to the company with any questions on this.
And in the meantime: If you’re attending the 2025 American Academy of Ophthalmology (AAO) annual meeting this weekend (Oct. 18-20), stop by the BVI booth (#3521) for a look.